Success Story: NIW Approved Without RFE! We Helped a Biotechnology Researcher Secure Success
On April 21st, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Post-Doctoral Fellow in the Field of Biotechnology (Approval Notice).
General Field: Biotechnology
Position at the Time of Case Filing: Post-Doctoral Fellow
Country of Origin: Bahrain
State of Residence at the Time of Filing: Oklahoma
Approval Notice Date: April 21st, 2026
Processing Time: 8 months, 2 days (Premium Processing Upgrade Requested)
Case Summary:
A biotechnology researcher with a Ph.D. in biotechnology secured approval of the I-140 NIW petition through a strong presentation of research at the intersection of cancer survivorship, metabolic dysfunction, and diabetes prevention. The client is currently employed in a research role and continues to develop molecular and cellular profiling approaches to identify biomarkers and targeted interventions for estrogen receptor-positive breast cancer survivors undergoing endocrine therapy.
Key Credentials Presented in the Petition
- Ph.D. in biotechnology
- 16 peer-reviewed journal articles, including 5 first-authored articles
- 2 conference abstracts, including 1 first-authored abstract
- 311 citations to the client’s published work
- At least 51 completed peer reviews
- Research funding support through the Harold Hamm Diabetes Center Novel Pilot Project for Post-Docs Grant Program
Research Focus and National Importance
The petition framed the client’s proposed endeavor as a biotechnology research effort with clear public health value. The client’s work focuses on developing advanced molecular and cellular profiling methods to study adipose, pancreatic, and liver tissues, with the goal of identifying biomarkers and targeted interventions that may help prevent diabetes and metabolic dysfunction in breast cancer survivors receiving endocrine therapy.
Rather than relying on the importance of the topic alone, the petition connected the client’s work to broader U.S. healthcare priorities, including cancer survivorship, chronic disease prevention, diabetes-related healthcare burden, and precision medicine. This helped demonstrate that the proposed endeavor had both substantial merit and national importance.
NIW Approval and Outlook
The I-140 NIW approval recognized the strength of the client’s biotechnology background, documented research influence, funding-supported work, and continued commitment to improving long-term outcomes for breast cancer survivors. We congratulate the client on this important approval and wish the client continued success in advancing research that supports diabetes prevention, precision medicine, and better survivorship care in the United States.